This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Constitutional aplastic anaemia원발성 무형성(순수)적혈구

ICD-10: D61.0 | Synonyms: congenital aplastic anemia, Constitutional aplastic anemia, Inherited aplastic anemia, Primary aplastic anemia

Contents
  1. History
  2. Causes
  3. Genetics
  4. General epidemiology
  5. Pathophysiology
  6. Symptoms
  7. Signs
  8. Screening
  9. Diagnosis
  10. Treatment
  11. Prognosis
  12. Prevention
  13. References

1. History

Establishment of the early concept

The concept of aplastic anemia began in 1888 when Paul Ehrlich first described pancytopenia and fatty marrow in a young pregnant woman. Subsequently, Vaquez and Aubertin (1904) systematically classified aplastic anemia as a bone marrow failure syndrome. The concept of 'constitutional' or 'primary' aplastic anemia took shape in the 1930s–1950s as familial occurrence and association with other congenital anomalies were recognized.

Elucidation of the genetic basis of congenital aplastic anemia

In 1927, Fanconi described a syndrome of pancytopenia with multiple congenital malformations in 3 siblings, establishing Fanconi anemia as a separate entity. Diamond-Blackfan syndrome was described by Diamond and Blackfan in 1938 as congenital pure red cell aplasia. Later, in the 1990s–2000s, telomerase gene mutations (TERC, TERT) were found to be associated with bone marrow failure syndromes related to dyskeratosis congenita.

Modern classification system

Currently, congenital/primary aplastic anemia is used as a concept encompassing various inherited bone marrow failure syndromes, including Fanconi anemia, Diamond-Blackfan syndrome, dyskeratosis congenita, Shwachman-Diamond syndrome, and familial hypoplastic anemia. These are divided according to the type of gene defect into DNA damage repair defects, ribosome biogenesis abnormalities, and telomere maintenance abnormalities.

2. Causes

Gene mutations

Congenital/primary aplastic anemia is caused by mutations in a variety of genes. Major causative genes include the FANC gene family (Fanconi anemia), RPS19 and other ribosomal protein genes (Diamond-Blackfan), telomere maintenance genes such as DKC1, TERC, and TERT (dyskeratosis congenita), and SBDS (Shwachman-Diamond syndrome).

Intrinsic defects of hematopoietic stem cells

In primary aplastic anemia, an intrinsic defect exists in the hematopoietic stem cells themselves. Mechanisms such as abnormalities of DNA repair pathways, impaired ribosome biogenesis, and telomere shortening reduce the proliferative and differentiation capacity of hematopoietic stem cells. DNA damage accumulated during repeated cell divisions induces apoptosis or premature senescence.

Secondary immune abnormalities

In some congenital aplastic anemias, in addition to the primary genetic defect, a secondary autoimmune response may accompany it and further suppress bone marrow function. In addition, because of genetic instability, the risk of secondary malignancies (myelodysplastic syndrome, acute leukemia) increases.

3. Genetics

Mode of inheritance

The inheritance pattern varies depending on the syndrome causing congenital aplastic anemia. Most follow autosomal recessive inheritance (Fanconi anemia, Shwachman-Diamond syndrome). Diamond-Blackfan syndrome mainly follows autosomal dominant inheritance, and about 40–45% are de novo mutations. An X-linked form (DKC1 gene) is observed in some cases of dyskeratosis congenita.

Major genes and mutations

Fanconi anemia is caused by mutations in more than 22 FANC genes, and FANCA mutations account for about 60–65% of the total. In Diamond-Blackfan syndrome, RPS19 mutations account for about 25%, and mutations in many ribosomal genes such as RPL5, RPL11, and RPL35A have been reported. In dyskeratosis congenita, mutations in more than 10 genes are known, including DKC1 (X-linked), TERC (autosomal dominant), TERT (autosomal dominant/recessive), RTEL1, and TINF2.

Importance of genetic testing

Accurate genetic diagnosis is essential for assessing the risk of secondary tumors, selecting the optimal treatment method (especially the need to reduce radiation and alkylating agent conditioning), screening siblings for carrier status, and family counseling.

4. General epidemiology

Worldwide incidence

The overall incidence of inherited bone marrow failure syndromes, including congenital/primary aplastic anemia, is estimated at about 5–10 per 1 million births. The annual incidence of Fanconi anemia is about 1–3 per 1 million births, and that of Diamond-Blackfan syndrome is estimated at 5–10 per 1 million births.

Status in Korea

In Korea, congenital aplastic anemia is included among rare diseases eligible for Special Copayment Reduction. The number of patients in Korea with congenital bone marrow failure syndromes such as Fanconi anemia and Diamond-Blackfan syndrome is estimated at around several hundred, and the gene mutation spectrum and clinical characteristics have been reported through single-center cohort studies in Korea. Care is provided in specialized pediatric hematology-oncology departments and hematopoietic stem cell transplantation centers.

Characteristics of pediatric and adult occurrence

Most congenital aplastic anemias are diagnosed in childhood. The mean age at diagnosis is 7–8 years for Fanconi anemia and from a few months after birth to within 1 year for Diamond-Blackfan syndrome. Some mild phenotypes are first diagnosed in adulthood.

5. Pathophysiology

Abnormalities of the DNA damage repair pathway

In Fanconi anemia, FANC proteins play an essential role in the repair of DNA interstrand crosslinks (ICL). The FANC protein complex recognizes ICL sites and activates the ICL repair pathway through monoubiquitination of the FANCD2 protein. When this pathway is defective, ICLs accumulate in hematopoietic stem cells, increasing DNA double-strand breaks, cell death, and genetic instability.

Abnormal ribosome biogenesis and p53 activation

In Diamond-Blackfan syndrome, haploinsufficiency of ribosomal protein genes causes impaired ribosome biogenesis, and free ribosomal proteins (especially RPL5, RPL11) bind to MDM2 and inhibit its p53-degrading function. As a result, p53 is stabilized, increasing cell-cycle arrest and apoptosis, which is especially prominent in erythroid precursors.

Telomere shortening and hematopoietic stem cell aging

In dyskeratosis congenita, defects in telomere maintenance genes cause telomeres to shorten abnormally rapidly. Telomere shortening induces replicative senescence, exhausting the proliferative capacity of hematopoietic stem cells. This vulnerability is especially evident in hematopoietic stem cells, which divide frequently.

6. Symptoms

Symptoms due to pancytopenia

The main symptoms of congenital aplastic anemia are determined by the three components of pancytopenia. The main symptoms are fatigue, pallor, and dyspnea due to anemia; recurrent infections and fever due to neutropenia; and bleeding (petechiae, epistaxis, gum bleeding, menorrhagia) due to thrombocytopenia.

Congenital malformations and physical findings

In Fanconi anemia, various congenital physical anomalies are present, such as skin pigmentation abnormalities (café-au-lait spots, hypopigmented spots), thumb and radial anomalies, microcephaly, renal malformations (horseshoe kidney, renal agenesis), and short stature. In Diamond-Blackfan syndrome, thumb anomalies, cleft palate, and cardiac malformations may be present.

Timing of symptom onset

Onset in childhood is typical, but in mild phenotypes diagnosis may be delayed until adulthood. In Fanconi anemia in particular, congenital physical anomalies are often detected first, before aplastic anemia develops.

7. Signs

Physical examination findings

Pallor, petechiae and bruising, mucosal bleeding, and findings of recurrent infection are common signs. In Fanconi anemia, characteristic physical anomalies such as thumb and radial malformations, pigmented skin lesions, microcephaly, short stature, and delayed sexual development are observed. Splenomegaly is absent or mild.

Laboratory findings

The complete blood count shows pancytopenia (anemia, neutropenia, thrombocytopenia). Red blood cells tend to be macrocytic, and fetal hemoglobin (HbF) levels are elevated. Bone marrow examination is characterized by decreased cellularity, fatty replacement, and morphological abnormalities of the remaining cells.

Chromosome fragility testing

The standard test for diagnosing Fanconi anemia is chromosome fragility testing using diepoxybutane (DEB) or mitomycin C (MMC). In patients with Fanconi anemia, markedly more abnormalities such as chromosome breaks and radial configurations are observed after DEB/MMC treatment compared with normal individuals.

8. Screening

Newborn screening and family screening

A standard newborn screening program for congenital aplastic anemia has not yet been established. However, children born to parents who are Fanconi anemia carriers are screened after birth with genetic testing including the DEB test. In known Fanconi anemia families, sibling carrier screening for hematopoietic stem cell transplantation of siblings is also important.

Screening based on clinical suspicion

In children with unexplained pancytopenia, especially when accompanied by congenital physical anomalies, congenital aplastic anemia is suspected, and DEB testing and NGS gene panel testing are performed. Among patients diagnosed with aplastic anemia, differentiation from congenital forms when evaluating the response to immunosuppressive therapy before hematopoietic stem cell transplantation is important.

Prenatal diagnosis

In families in which a gene mutation has been identified, prenatal genetic testing by preimplantation genetic testing (PGT-M) or chorionic villus sampling is possible.

9. Diagnosis

Clinical diagnostic criteria

To diagnose congenital aplastic anemia, after confirming pancytopenia on the complete blood count, hypocellular marrow (<25%) on bone marrow examination, and elevated fetal hemoglobin, special tests are performed to identify the cause. The presence or absence of associated congenital malformations on clinical findings provides diagnostic clues.

Chromosome fragility and genetic testing

When Fanconi anemia is suspected, DEB/MMC-induced chromosome fragility testing is performed. Even if this test is negative, when clinically suspected, the test is repeated in fibroblasts or bone marrow cells to exclude mosaicism. Next-generation sequencing (NGS)-based inherited bone marrow failure syndrome panel testing is becoming established as the standard test for identifying the causative gene.

Differential diagnosis

Differentiation is required from acquired aplastic anemia, myelodysplastic syndrome, paroxysmal nocturnal hemoglobinuria (PNH), Diamond-Blackfan syndrome, Shwachman-Diamond syndrome, and dyskeratosis congenita. PNH clone testing (flow cytometry for GPI-deficient cells) confirms an association with acquired aplastic anemia.

10. Treatment

Hematopoietic stem cell transplantation

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment for congenital aplastic anemia. An HLA-matched sibling donor (MSD) is preferred whenever possible, and if none is available, an HLA-matched unrelated donor (MUD) or haploidentical transplantation is considered. In Fanconi anemia, because of the DNA repair defect, there is hypersensitivity to alkylating agents and radiation, so the conditioning intensity must be reduced.

Androgen therapy

Androgens (danazol, oxymetholone) can stimulate hematopoiesis and improve blood counts, and are used particularly in Fanconi anemia and dyskeratosis congenita before transplantation or in patients for whom transplantation is not possible. The response rate is about 50–60%, but adverse effects such as virilization and hepatotoxicity (hepatocellular adenoma, liver cancer) require caution.

Supportive care and surveillance for secondary tumors

Transfusion (red blood cells, platelets), hematopoietic growth factors (G-CSF), and prevention and treatment of infection are the core of supportive care. In Fanconi anemia, the risk of secondary malignancies such as head and neck squamous cell carcinoma, gynecologic cancers, gastrointestinal cancers, and acute leukemia/MDS is markedly high, so regular surveillance endoscopy and gynecologic examinations are essential.

11. Prognosis

Prognosis after transplantation

Hematopoietic stem cell transplantation from an HLA-matched sibling donor is reported to achieve long-term survival rates of 70–90%. Transplant outcomes vary with patient age, number of transfusions before transplantation, donor type, and reduced conditioning method.

Risk of secondary tumors

Patients with Fanconi anemia have a tens to hundreds of times higher risk of secondary malignancies (especially head and neck squamous cell carcinoma, gynecologic cancers, gastrointestinal cancers, AML/MDS) than the general population. Even after transplantation, the risk of secondary tumors does not disappear completely, so long-term follow-up is essential.

Prognostic factors

Early diagnosis, availability of an HLA-matched donor, selection of an appropriate conditioning method, and prevention of transplant-related complications (graft-versus-host disease, infection) are the key factors determining prognosis. The quality of life of survivors depends on prevention of secondary tumors and management of endocrine and organ complications.

12. Prevention

Genetic counseling and prenatal diagnosis

Genetic counseling is provided to families of patients with congenital aplastic anemia, and when a gene mutation is identified, the birth of an affected fetus can be prevented through prenatal genetic testing (CVS, amniocentesis) or preimplantation genetic testing (PGT-M). It is also used to identify siblings who are HLA-matched donors.

Prevention and management of secondary tumors

To prevent secondary tumors in patients with Fanconi anemia, exposure to tobacco, alcohol, and carcinogenic environmental factors is avoided, and surveillance programs such as regular head and neck endoscopy, obstetric-gynecologic examinations, and colonoscopy are followed. Human papillomavirus (HPV) vaccination is recommended for the prevention of gynecologic and head and neck cancers.

Follow-up to prevent complications

Regular multidisciplinary follow-up is required to prevent endocrine complications (growth impairment, diabetes, hypothyroidism), hepatic complications (during androgen therapy), decreased bone density, neurocognitive developmental abnormalities, and transplant-related complications (graft-versus-host disease, infertility).

13. References

  1. Shimamura A, Alter BP. Pathophysiology and management of inherited bone marrow failure syndromes. Blood Rev. 2010;24(3):101-122.
  2. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006;108(8):2509-2519.
  3. Dokal I. Dyskeratosis congenita. Hematology Am Soc Hematol Educ Program. 2011;2011:480-486.
  4. Alter BP. Fanconi anemia and the development of leukemia. Best Pract Res Clin Haematol. 2014;27(3-4):214-221.
  5. Lipton JM, Ellis SR. Diamond-Blackfan anemia: diagnosis, treatment, and molecular pathogenesis. Hematol Oncol Clin North Am. 2009;23(2):261-282.
  6. Vlachos A, Ball S, Dahl N, et al. Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference. Br J Haematol. 2008;142(6):859-876.
  7. Dufour C, Svahn J. Fanconi anaemia: new strategies. Bone Marrow Transplant. 2008;41(Suppl 2):S90-S95.
  8. Bagby GC, Alter BP. Fanconi anemia. Semin Hematol. 2006;43(3):147-156.
  9. Park SY, Lee SY, Cho BS. Diagnosis and treatment of aplastic anemia in children. Clinical Pediatric Hematology-Oncology. 2018;25(2):55-65.
  10. Savage SA, Dufour C. Classical inherited bone marrow failure syndromes with high risk for myelodysplastic syndrome and acute myelogenous leukemia. Semin Hematol. 2017;54(2):105-114.
  11. Garaycoechea JI, Crossan GP, Langevin F, Daly M, Arends MJ, Patel KJ. Genotoxic consequences of endogenous aldehydes on mouse haematopoietic stem cell function. Nature. 2012;489(7417):571-575.
  12. Mehta PA, Tolar J. Fanconi Anemia. In: Adam MP, et al. eds. GeneReviews. University of Washington, Seattle; 2002 (updated 2022).